

Viral Vector & Plasmid DNA Manufacturing Market Report: Trends, Forecast and Competitive Analysis

<https://marketpublishers.com/r/V6C7E56E2759EN.html>

Date: May 2024

Pages: 150

Price: US\$ 4,850.00 (Single User License)

ID: V6C7E56E2759EN

Abstracts

Get it in 2 to 4 weeks by ordering today

The future of the viral vector & plasmid DNA manufacturing market looks promising with opportunities in antisense & RNAi, gene therapy, cell therapy, and vaccinology. The global viral vector & plasmid DNA manufacturing market is expected to grow with a CAGR of 14%-16% from 2020 to 2025. The major drivers for this market are technological advancements to mitigate challenges posed by conventional methods of vector production, increase in the number of clinical studies, and a growing number of gene therapy cases.

A total of XX figures / charts and XX tables are provided in this more than 150 pages report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global viral vector & plasmid DNA manufacturing market report, please download the report brochure.

In this market, viral vector is the largest product segment of viral vector & plasmid DNA manufacturing, whereas pharmaceutical and biopharmaceutical companies is the largest end user. Growth in various segments of the viral vector & plasmid DNA manufacturing market are given below:

The study includes trends and forecast for the global viral vector & plasmid DNA manufacturing market by product, workflow, application, end use, disease, and region as follows:

By Product [Value (\$ Million) shipment analysis for 2014 – 2025]:

Viral Vector

Plasmid DNA

Non Viral Vector

By Workflow [Value (\$ Million) shipment analysis for 2014 – 2025]:

Upstream Processing

Downstream Processing

By Application [Value (\$ Million) shipment analysis for 2014 – 2025]:

Antisense & RNAi

Gene Therapy

Cell Therapy

Vaccinology

By End Use [Value (\$ Million) shipment analysis for 2014 – 2025]:

Pharmaceutical and Biopharmaceutical Companies

Research Institutes

By Disease [Value (\$ Million) shipment analysis for 2014 – 2025]:

Cancer

Genetic Disorders

Infectious Diseases

Others

By Region [Value (\$ Million) shipment analysis for 2014 – 2025]:

North America

United States

Canada

Mexico

Europe

United Kingdom

Spain

Germany

France

Asia Pacific

China

India

Japan

The Rest of the World

Brazil

Some of the viral vector & plasmid DNA manufacturing companies profiled in this report include Kaneka Eurogentec, FinVector, Brammer Bio, Cell and Gene Therapy Catapult,

FUJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, Cobra Biologics, UniQure and MassBiologics.

Lucintel forecasts that viral vector will remain the largest product segment over the forecast period due to necessity and applicability of this product in different research interventions.

Within this market, pharmaceutical and biotechnology companies will remain the largest end use segment over the forecast period due to continuous introduction of advanced therapies coupled with a subsequent increase in the number of gene therapy-based discovery programs by companies.

North America will remain the largest region over the forecast period due to the fact that the United States has been a major destination for all the recent advancements in the field of medicine. Increasing investments in gene therapy products in the United States have led to the growth of the market studied in recent years. In the United States, regulatory encouragement and patient advocacy have pushed rare disease clinical research to the center stage.

Features of the Global Viral Vector & Plasmid DNA Manufacturing Market

Market Size Estimates: Global viral vector & plasmid DNA manufacturing market size estimation in terms of value (\$M) shipment.

Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.

Segmentation Analysis: Global viral vector & plasmid DNA manufacturing market size by various segments, such as product, workflow, application, end use, and disease in terms of value.

Regional Analysis: Global viral vector & plasmid DNA manufacturing market breakdown by the North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product, workflow, application, end use, disease, and region for the global viral vector & plasmid DNA manufacturing market.

Strategic Analysis: This includes M&A, new product development, and

competitive landscape of the global viral vector & plasmid DNA manufacturing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following key questions

- Q.1 What are some of the most promising potential, high-growth opportunities for the global viral vector & plasmid DNA manufacturing market by products (viral vector, plasmid DNA, and non viral vector), workflow (upstream processing and downstream processing), application (antisense & RNAi, gene therapy, cell therapy, and vaccinology), end-use (pharmaceutical and biopharmaceutical companies and research institutes), disease (cancer, genetic disorders, infectious diseases, and others), and region (North America, Europe, Asia Pacific, and Rest of the World)?
- Q.2 Which segments will grow at a faster pace and why?
- Q.3 Which region will grow at a faster pace and why?
- Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global viral vector & plasmid DNA manufacturing market?
- Q.5 What are the business risks and threats to the global viral vector & plasmid DNA manufacturing market?
- Q.6 What are the emerging trends in this global viral vector & plasmid DNA manufacturing market and the reasons behind them?
- Q.7 What are some changing demands of customers in this global viral vector & plasmid DNA manufacturing market?
- Q.8 What are the new developments in this global viral vector & plasmid DNA manufacturing market? Which companies are leading these developments?
- Q.9 Who are the major players in this global viral vector & plasmid DNA manufacturing market? What strategic initiatives are being implemented by key players for business growth?
- Q.10 What are some of the competitive products and processes in this global viral vector & plasmid DNA manufacturing market, and how big of a threat do they pose for loss of market share via material or product substitution?
- Q.11 What M&A activities did take place in the last five years in the global viral vector & plasmid DNA manufacturing market?

Report Details

Key Features Description

Base Year for Estimation 2019

Trend Period

(Actual Estimates) 2014-2019

Forecast Period 2020-2025

Pages More than 150

Market Representation / Units Revenue in US \$ Million

Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling

Market Segments Products (Viral Vector, Plasmid DNA, and Non Viral Vector), Workflow (Upstream Processing and Downstream Processing), Application (Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology), End-Use (Pharmaceutical and Biopharmaceutical Companies and Research Institutes), and Disease (Cancer, Genetic Disorders, Infectious Diseases, and Others)

Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)

Customization 10% Customization without Any Additional Cost

Contents

1. EXECUTIVE SUMMARY

2. MARKET BACKGROUND AND CLASSIFICATIONS

2.1: Introduction, Background, and Classifications

2.2: Supply Chain

2.3: Industry Drivers and Challenges

3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025

3.1: Macroeconomic Trends and Forecast

3.2: Global Viral Vector & Plasmid DNA Manufacturing Market Trends and Forecast

3.3: Global Viral Vector & Plasmid DNA Manufacturing Market by Product

3.3.1: Viral Vector

3.3.2: Plasmid DNA

3.3.3: Non Viral Vector

3.4: Global Viral Vector & Plasmid DNA Manufacturing Market by Workflow

3.4.1: Upstream Processing

3.4.2: Downstream Processing

3.5: Global Viral Vector & Plasmid DNA Manufacturing Market by Application

3.5.1: Antisense & RNAi

3.5.2: Gene Therapy

3.5.3: Cell Therapy

3.5.4: Vaccinology Fish

3.6: Global Viral Vector & Plasmid DNA Manufacturing Market by End Use

3.6.1: Pharmaceutical and Biopharmaceutical Companies

3.6.2: Research Institutes

3.7: Global Viral Vector & Plasmid DNA Manufacturing Market by Disease

3.7.1: Cancer

3.7.2: Genetic Disorders

3.7.3: Infectious Diseases

3.7.4: Other

4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION

4.1: Global Viral Vector & Plasmid DNA Manufacturing Market by Region

4.2: North American Viral Vector & Plasmid DNA Manufacturing Market

- 4.2.1: Market by Product: Viral Vector, Plasmid DNA, and Non Viral Vector,
- 4.2.2: Market by Workflow: Upstream Processing and Downstream Processing
- 4.2.3: Market by Application: Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology
- 4.2.4: Market by End-Use: Pharmaceutical and Biopharmaceutical Companies and Research Institutes
- 4.2.5: Market by Disease: Cancer, Genetic Disorders, Infectious Diseases, and Others
- 4.2.6: The United States Viral Vector & Plasmid DNA Manufacturing Market
- 4.2.7: The Canadian Viral Vector & Plasmid DNA Manufacturing Market
- 4.2.8: The Mexican Viral Vector & Plasmid DNA Manufacturing Market
- 4.3: European Viral Vector & Plasmid DNA Manufacturing Market
 - 4.3.1: Market by Product: Viral Vector, Plasmid DNA, and Non Viral Vector,
 - 4.3.2: Market by Workflow: Upstream Processing and Downstream Processing
 - 4.3.3: Market by Application: Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology
 - 4.3.4: Market by End-Use: Pharmaceutical and Biopharmaceutical Companies and Research Institutes
 - 4.3.5: Market by Disease: Cancer, Genetic Disorders, Infectious Diseases, and Others
 - 4.3.6: The United Kingdom Viral Vector & Plasmid DNA Manufacturing Market
 - 4.3.7: The Spanish Viral Vector & Plasmid DNA Manufacturing Market
 - 4.3.8: The German Viral Vector & Plasmid DNA Manufacturing Market
 - 4.3.9: The French Viral Vector & Plasmid DNA Manufacturing Market
- 4.4: APAC Viral Vector & Plasmid DNA Manufacturing Market
 - 4.4.1: Market by Product: Viral Vector, Plasmid DNA, and Non Viral Vector,
 - 4.4.2: Market by Workflow: Upstream Processing and Downstream Processing
 - 4.4.3: Market by Application: Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology
 - 4.4.4: Market by End-Use: Pharmaceutical and Biopharmaceutical Companies and Research Institutes
 - 4.4.5: Market by Disease: Cancer, Genetic Disorders, Infectious Diseases, and Others
 - 4.4.6: The Chinese Viral Vector & Plasmid DNA Manufacturing Market
 - 4.4.7: The Indian Viral Vector & Plasmid DNA Manufacturing Market
 - 4.4.8: The Japanese Viral Vector & Plasmid DNA Manufacturing Market
- 4.5: ROW Viral Vector & Plasmid DNA Manufacturing Market
 - 4.5.1: Market by Product: Viral Vector, Plasmid DNA, and Non Viral Vector,
 - 4.5.2: Market by Workflow: Upstream Processing and Downstream Processing
 - 4.5.3: Market by Application: Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology
 - 4.5.4: Market by End-Use: Pharmaceutical and Biopharmaceutical Companies and

Research Institutes

4.5.5: Market by Disease: Cancer, Genetic Disorders, Infectious Diseases, and Others

4.5.5: Brazilian Viral Vector & Plasmid DNA Manufacturing Market

5. COMPETITOR ANALYSIS

5.1: Market Share Analysis

5.2: Product Portfolio Analysis

5.3: Operational Integration

5.4: Geographical Reach

5.5: Porter's Five Forces Analysis

6. COST STRUCTURE ANALYSIS

6.1: Cost of Goods Sold

6.2: SG&A

6.3: EBITDA Margin

7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS

7.1: Growth Opportunity Analysis

7.1.1: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Product

7.1.2: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Workflow

7.1.3: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Application

7.1.4: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by End Use

7.1.5: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Disease

7.1.6: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Region

7.2: Emerging Trends in the Global Viral Vector & Plasmid DNA Manufacturing Market

7.3: Strategic Analysis

7.3.1: New Product Development

7.3.2: Capacity Expansion of the Global Viral Vector & Plasmid DNA Manufacturing Market

7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Viral Vector & Plasmid

DNA Manufacturing Market

7.3.4: Certification and Licensing

8. COMPANY PROFILES OF LEADING PLAYERS

8.1: Kaneka Eurogentec

8.2: FinVector

8.3: Brammer Bio

8.4: Cell and Gene Therapy Catapult

8.5: FUJIFILM Diosynth Biotechnologies

8.6: Sanofi

8.7: Spark Therapeutics

8.8: Cobra Biologics

8.9: UniQure

8.10: MassBiologics

I would like to order

Product name: Viral Vector & Plasmid DNA Manufacturing Market Report: Trends, Forecast and Competitive Analysis

Product link: <https://marketpublishers.com/r/V6C7E56E2759EN.html>

Price: US\$ 4,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V6C7E56E2759EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

